se gb

NEWS

Aprea Therapeutics Announces Presentation at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

BOSTON, MA., and STOCKHOLM, SWEDEN, January 5, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief Executive Officer, is scheduled to present a company update and overview at the 35th Annual J.P. Morgan Healthcare Conference at 7:30a.m. PT on Wednesday, January 11, 2017 at the Westin St. Francis Hotel in San Francisco, CA.

2017-01-05

Karolinska Development portfolio company Dilafor initiates Phase IIb clinical trial with tafoxiparin in women with protracted labor

STOCKHOLM – January 4, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase IIb study with tafoxiparin in pregnant women who experience slow progress of labor or labor arrest after spontaneous onset.

2017-01-04

Karolinska Development portfolio company Dilafor AB granted U.S. patent for Phase II drug tafoxiparin

STOCKHOLM, SWEDEN – December 2, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has been granted a U.S. patent protecting its proprietary compound tafoxiparin.

2016-12-02

Karolinska Development company Modus Therapeutics to present poster at 58th ASH Annual Meeting in San Diego

STOCKHOLM – December 1, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the announcement today from its portfolio company Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle cell disease (SCD), will present a poster at the 58th American Society of Hematology (ASH) Annual Meeting in San Diego on 4th December. The ASH Annual Meeting is a world-leading event in malignant and non-malignant hematology.

2016-12-01

Karolinska Development company Modus Therapeutics’ ongoing clinical study with sevuparin in sickle cell disease expands to include adolescent patients

STOCKHOLM – November 15, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the announcement today from its portfolio company Modus Therapeutics AB that, after a planned safety review by an independent Data Safety Monitoring Board, adolescents between the age of 12 and 18 will now be enrolled into its ongoing clinical study with sevuparin for sickle cell disease (SCD). In addition, Modus Therapeutics has decided to increase the sample size of the current Phase II study to around 150 patients in total, so that this study can play a more important role in the overall clinical program needed to register sevuparin.

2016-11-22

Trinity Delta Report

Trinity Delta Report - November 2016

2016-11-18

Karolinska Development company Modus Therapeutics’ ongoing clinical study with sevuparin in sickle cell disease expands to include adolescent patients

STOCKHOLM – November 15, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the announcement today from its portfolio company Modus Therapeutics AB that, after a planned safety review by an independent Data Safety Monitoring Board, adolescents between the age of 12 and 18 will now be enrolled into its ongoing clinical study with sevuparin for sickle cell disease (SCD). In addition, Modus Therapeutics has decided to increase the sample size of the current Phase II study to around 150 patients in total, so that this study can play a more important role in the overall clinical program needed to register sevuparin.

2016-11-15

Karolinska Development company Modus Therapeutics granted U.S. patents for sickle cell disease drug candidate sevuparin

STOCKHOLM – November 7, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) notes the announcement today from its portfolio company Modus Therapeutics AB that it has been granted two patents in the U.S. covering its proprietary drug candidate sevuparin. More specifically, the two patents have been granted claims for the substance sevuparin per se and a manufacturing method for producing sevuparin (U.S. Patent no. 9,480,701) as well as its use in e.g. sickle cell disease (U.S. Patent No. 9,480,702).

2016-11-07

Karolinska Development portfolio company Promimic AB appoints new Chairman and Directors to its Board

STOCKHOLM – October 27, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic AB, an innovative biomaterials company, has elected Tord Lendau as Chairman of the Board of Directors, and Håkan Krook and Patrik Sjöstrand as Non-executive Directors.

2016-10-27

Karolinska Development portfolio company Promimic and Danco announce completion of US production line for HAnano Surface medical implant coating

STOCKHOLM – October 19, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic AB, an innovative biomaterials company, and its partner Danco Anodizing have successfully completed the production line in the USA for Promimic’s HAnano Surface coating for orthopedic and dental implants.

2016-10-19

Karolinska Development portfolio company Aprea Therapeutics enrolls first patients in Phase II trial of APR-246 in ovarian cancer

STOCKHOLM, SWEDEN – October 10, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics AB announced today that it enrolled the first patients in the Phase II part of the ongoing PiSARRO clinical study of APR-246 for the treatment of high-grade serous ovarian cancer.

2016-10-10

Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib trial of APR-246 in ovarian cancer

Efficacy and safety data for APR-246 in high grade serous ovarian cancer presented at ESMO 2016 annual meeting

2016-10-10

Karolinska Development portfolio company Dilafor AB raises SEK 51 million to facilitate Phase IIb clinical study with tafoxiparin

STOCKHOLM – September 27, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has successfully completed a financing round raising SEK 51 million (US$5.9 million) from new and existing investors. New investors include Lee's Healthcare Industry Fund, Rosetta Capital IV and Pila AB.

2016-09-27

Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research

STOCKHOLM – September 20, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company BioArctic AB has entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications.

2016-09-20

Karolinska Development portfolio company Promimic AB raises SEK 23.8 million to establish commercial operations in the US

STOCKHOLM – September 13, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic AB, an innovative biomaterials company, has secured SEK 23.8 million (US$3.2 million) in a new share issue to finance the establishment of its commercial operations in the US, the world’s largest market for medical implants. Chalmers Ventures, one of Sweden’s most prolific investors in innovative businesses, participated as a new investor alongside existing investors KDev Investments (an investment fund jointly owned by Karolinska Development and Rosetta Capital) and Almi Invest.

2016-09-13

Dilaforette to present at SCD Therapeutics Conference in New York

STOCKHOLM – 7th SEPTEMBER, 2016. Dilaforette, a Karolinska Development (STO:KDEV) portfolio company focused on developing sevuparin, an innovative treatment for patients with sickle cell disease, announces CEO Christina Herder is to present at the 5th Annual Sickle-Cell Disease (SCD) Therapeutics Conference on 8th September 2016 in New York.

2016-09-07

Preliminary data from a retrospective study indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.

In a retrospective study of patients undergoing cranioplasty using OSSDSIGN Cranial, 96,7% of patients treated showed no signs of post-operative complications leading to implant removal at an average follow-up time of 9,5 months. This indicates that OSSDSIGN Cranial may provide a better, more permanent solution for cranioplasty, even in a complex patient population.

2016-09-05

Karolinska Development: Interim Report for January-June 2016

STOCKHOLM – August 31, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report for the period January – June 2016. The Company will host a conference call and webcast today at 2 pm CEST – details below. The full report is available on the Company's website.

2016-08-31

Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors

STOCKHOLM/UMEÅ – July 6, 2016. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel treatment for hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Bruce Scharschmidt has been appointed as a new member of its board of directors and Senior Development Adviser.

2016-07-06

Aprea AB Names Christian S. Schade President & Chief Executive Officer

Boston, MA, and Stockholm, Sweden, June 16, 2016 – Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S. Schade has been named President and Chief Executive Officer. Mr. Schade, who will be based in Boston, has more than 30 years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in the investment banking industry. Prior to joining Aprea, he was Chief Executive Officer of Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson in an all-cash transaction.

2016-06-16

Dilaforette poster presentation at EHA Congress

STOCKHOLM – 9 JUNE, 2016. Dilaforette AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with Sickle Cell Disease, announces it will have a poster presentation at the European Hematology Association Congress in Copenhagen.

2016-06-08

Aprea AB announces efficacy and safety data in high-grade serous ovarian cancer patients treated with investigational APR-246 presented at 2016 ASCO Annual Meeting

June 7, 2016, Stockholm, Sweden - Aprea AB, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial in collaboration with the European Network for Translational Research in Ovarian Cancer (EUTROC). Aprea’s PiSARRO trial is investigating the safety and efficacy of APR-246 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with relapsed high-grade serous ovarian cancer. Results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) showed:

2016-06-07

Lipidor and Cadila Pharmaceuticals announce agreement on Phase III Clinical Study and joint commercialization of topical Psoriasis product

Lipidor AB and Cadila Pharmaceuticals Limited, one of the largest pharmaceutical manufacturing groups in India, have entered into a collaboration agreement on the commercialization of a sprayable anti-psoriatic product consisting of the generic Vitamin D analogue, Calcipotriol, formulated with Lipidor´s patented lipid-based drug delivery technology, AKVANO®. The product targets patients with mild to moderate psoriasis. Under the collaboration agreement, Cadila Pharmaceuticals will conduct a Phase III program in India starting in 2016.

2016-06-01

OssDsign appoints Simon Cartmell as Chairman of the Board - Strengthens organization ahead of the US Launch of its Novel Regenerative Facial and Cranial Implants in 2017

Uppsala, Sweden, 20 April, 2016 OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial repair, today announced the appointment of Simon Cartmell as Chairman of the Board. Mr Cartmell is an experienced entrepreneur in the life-sciences industry and a Non-Executive Director/Chairman of a number European medical device companies.

2016-04-20

Karolinska Development’s portfolio company Promimic AB announces that its HAnano Surface improves implant-to-bone integration for PEEK implants

GÖTEBORG 2016-04-08 – Promimic AB today announced the results of an in vivo proof of concept study on Polyether ether ketone (PEEK) implants coated with nano-sized hydroxyapatite published in International Journal of Nanomedicine.

2016-04-08

Promimic and Danco Anodizing in a Strategic Partnership

WARSAW, IN, USA AND GOTHENBURG, SWEDEN – MARCH 17, 2016. Promimic and Danco today signed a license agreement where Danco will invest in a production line for the HAnano Surface process developed by Promimic. Danco will be the preferred process partner for Promimic for the USA and China medical implant market.

2016-03-29

Cancer Company Aprea Closes EUR 46 Million (~USD 51 Million) Series B Financing

STOCKHOLM, SWEDEN, March 9, 2016 - Aprea AB, a clinical-stage biotechnology company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that it has completed a Series B financing round, raising EUR 46 million (approximately USD 51 million). The international syndicate was co-led by Versant Ventures and 5AM Ventures, with participation by Sectoral Asset Management. HealthCap acted as the local lead investor. Aprea’s main shareholder is KDev Investments AB, an investment vehicle owned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd.

2016-03-09

Karolinska Development portfolio company Dilaforette signs clinical collaboration agreement with Arabian Gulf University (Bahrain) for Phase 2 clinical development of sevuparin for Sickle Cell Disease

STOCKHOLM – February 16th, 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilaforette AB, a company focused on innovative treatments for patients with sickle-cell disease, and Arabian Gulf University (AGU) in Bahrain, have signed a Clinical Collaboration agreement for the Phase 2 proof of concept trial of sevuparin in patients with Sickle Cell Disease (SCD) experiencing acute Vaso-Occlusive Crisis (VOC).

2016-02-16

Dilaforette appoints new VP of Development

STOCKHOLM – 8th February, 2016. Dilaforette AB, a Karolinska Development (STO:KDEV) portfolio company focused on innovative treatments for patients with sickle-cell disease, announces the appointment of Lena Jendberg as its new Vice President of Development.

2016-02-08

Promimic launches dental implants with SIN

GOTHENBURG, SWEDEN – 28th of January 2016. Promimic today announced that the company's strategic partners Sistema de Implante Nacional (SIN) has initiated the launch of the first dental implant coated with Promimic's implant surface HAnano Surface. The implant is launched at CIOSP, the second largest dental trade show in the world, which is currently ongoing in São Paulo with over 100,000 visitors.

2016-01-28

Akinion Pharmaceuticals AB appoints Dr Richard Jones as CEO

STOCKHOLM, SWEDEN – January 19th 2016. Akinion Pharmaceuticals AB, a private biotechnology company developing AKN-028, a dual mechanism inhibitor of the oncogenic FMS-like tyrosine kinase-3 (FLT3) receptor and a downstream DNA repair target for the treatment of acute myeloid leukemia (AML), today announced the appointment of Dr Richard Jones as Chief Executive Officer. Akinion’s majority shareholder is KDev Investments AB, an investment vehicle jointly owned by Karolinska Development AB and Rosetta Capital.

2016-01-19

Umecrine Cognition announces grant of a US patent protecting its lead candidate drug GR3027. The use of GR3027 as a novel therapy of hepatic encephalopathy is also acknowledged in recognized scientific publications.

STOCKHOLM – December 9, 2015. Umecrine Cognition AB today announces that the United States Patent and Trademark Office (USPTO) has granted a patent covering its lead candidate drug GR3027. The patent adds to a corresponding patent granted by the European Patent Office (EPO) earlier this year. Umecrine Cognition is also pleased to announce peer-reviewed scientific publications supporting the use of GR3027 as a novel therapy for hepatic encephalopathy.

2015-12-09

OssDsign raises SEK 93 million (EUR 9.6 million) for commercial expansion

UPPSALA - November 4, 2015. OssDsign AB today announced that it has successfully raised SEK 93 million (EUR 9.6 million), in a new equity financing. The financing is led by the new investors SEB Venture Capital and Fouriertransform with continued investment from Karolinska Development. The proceeds will be used for the market expansion of OssDsign’s product line of unique craniofacial implants based on an innovative material technology with excellent biological and biomechanical properties.

2015-11-04

Amendia and Promimic announce strategic venture on spine implant surface treatment

MARIETTA, GA AND GOTHENBURG, SWEDEN – OCTOBER 14, 2015. Amendia Inc., a leading provider of innovative spinal technologies, and Promimic AB, a forward-thinking supplier of surface treatments for orthopaedic implants, based in Gothenburg, Sweden, announced today that it entered into a strategic venture. The venture allows Amendia to develop Promimic’s signature HAnano Surface technology for use with Amendia’s progressive patient-focused spinal implants. The alliance is another of many milestones for Amendia in 2015 as the company rapidly bolsters their product line for scalable growth while simultaneously improving supplemental technology.

2015-10-14

Dilaforette and Ergomed Initiate Phase II Clinical Trial with Dilaforette’s Sevuparin in Sickle-Cell Disease

Stockholm, Sweden and Guildford, UK, – 13 October 2015: Dilaforette AB, a privately held Swedish drug development company focused on innovative treatments for patients with sickle-cell disease (SCD) and Ergomed plc (AIM: ERGO), a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announced that the first patient has been enrolled in the Phase II study with sevuparin in patients with SCD.

2015-10-13

Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy

STOCKHOLM – August 19, 2015. Umecrine Cognition AB are today pleased to announce the first publication of preclinical results of the company’s candidate drug GR3027 in the American Journal of Physiology. The data shows unique reversal of key neurological symptoms in animal models with hepatic encephalopathy (HE) symptoms that have previously not been seen in the treatment models used.

2015-08-19

Aprea strengthens its board

STOCKHOLM – July 21, 2015. Aprea AB, a Karolinska Development AB (STO: KDEV) portfolio company, announces that Bernd R. Seizinger has been elected as Executive Chairman and Jonathan Hepple a new member of the board.

2015-07-21

Aprea receives U.S. patent approval for pharmaceutical formulation of lead compound APR-246

STOCKHOLM – June 26, 2015. Aprea AB, a Karolinska Development AB (STO: KDEV) portfolio company, announced today that the United States Patent and Trademark Office has granted a patent covering a new pharmaceutical formulation of APR-246. The patented formulation enables long term storage which is essential for the future commercial use of APR-246.

2015-06-26

Stockholms Affärsänglar (Stockholm Business Angels) and Almi Invest make capital investment in Inhalation Sciences AB (ISAB)

STOCKHOLM, SWEDEN – June 25, 2015. ISAB is broadening its ownership base: venture finance company Stockholms Affärsänglar (STOAF), together with Almi Invest, become new minority share owners, with a significant initial capital investment. The new ownership and investment reflects ISABs strategy of commercializing its world-leading technology platform for inhalation R&D.

2015-06-25

Clanotech's lead compound in development, CLT-28643, has recently been granted a European Patent by the European Patent Office

STOCKHOLM – June 15, 2015. Clanotech AB, a company developing α5β1 integrin inhibiting products for ophthalmic use, announced that the European Patent Office recently granted the patent for its lead drug candidate CLT-28643.

2015-06-15

Clanotech to present CLT-28643 in the treatment of eye disease at BioTrinity 2015

Stockholm – May 12, 2015. Clanotech AB, today announced that it will present its lead compound CLT-28643 for the treatment of eye diseases at BioTrinity 2015, Europe’s leading Biopartnering and Investment Conference, to be held on 11-13 May at the Novotel London West.

2015-05-12

Clanotech receives orphan drug designation in the U.S.

STOCKHOLM – March 27, 2015. Clanotech AB announced today that its candidate drug CLT-28643 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for prevention of scarring after glaucoma surgery.

2015-03-27

Dilaforette receives Orphan Drug Designation in the U.S. for sevuparin in Sickle-Cell Disease

STOCKHOLM, SWEDEN - March 20, 2015. Dilaforette AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for sevuparin (DF02) for the treatment of patients with sickle-cell disease (SCD). The company is currently in the final stage of study preparation for a Phase II study in SCD with sevuparin and aim to start recruitment of patients during the first half of 2015.

2015-03-20

Aprea's unique p53 cancer treatment featured in BioWorld Today article

February 26, 2015. The newly published article in BioWorld Today covers the origin of Aprea's program aiming to reactivate non-functional tumor suppressor protein p53, the clinical data generated on the candidate drug APR-246, the treatment potential of APR-246 in ovarian cancer where a Phase I/II study is currently ongoing, and its potential use in other types of cancers.

2015-02-26

Dilafor announces positive results from a multi dosing safety and pharmacokinetic clinical study

STOCKHOLM, SWEDEN – February 25, 2015. Dilafor AB, a Karolinska Development portfolio company, announced today the completion of a safety and pharmacokinetic multi dosing clinical study with the candidate drug tafoxiparin. The purpose of the study was to evaluate different clinical administration routes and different dose levels of tafoxiparin in healthy female volunteers. The results will give guidance on the dosages to be used in the Phase II trial in labor induction expected to start in end 2015.

2015-02-25

Aprea granted European orphan drug designation for APR-246 in ovarian cancer

STOCKHOLM - January 22, 2015. Aprea AB, a Karolinska Development portfolio company, today announced that the European Medicines Agency (EMA) has granted its drug candidate APR-246 orphan drug designation for the treatment of ovarian cancer. Aprea is currently conducting a Phase Ib/II trial of APR-246 in combination with standard of care chemotherapy in patients with relapsed platinum sensitive high-grade serous ovarian cancer.

2015-01-22

Dilaforette receives positive COMP opinion on Orphan Drug Designation in the EU for sevuparin in Sickle-Cell Disease

STOCKHOLM, SWEDEN - January 19, 2015. Dilaforette AB today announced that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) on orphan drug designation in the EU for sevuparin (DF02) for the treatment of patients with sickle-cell disease (SCD). The opinion will now be forwarded to the European Commission for final ratification. The company is currently in final stage of study preparation for a Phase II study in SCD with sevuparin and aim to start recruitment of patients during the first half of 2015.

2015-01-19

Dilafor signs supply and partnership agreement with Opocrin

STOCKHOLM, SWEDEN and MODENA, ITALY – October 8, 2014. Dilafor AB and Opocrin S.p.A. announced today that they have entered into a commercial supply and partnership agreement. In the agreement, Opocrin will concurrently make an investment in Dilafor and be appointed as the main commercial manufacturing partner for Dilafor’s candidate drug tafoxiparin for the European, US, CIS and Japanese markets. Furthermore, Opocrin will supply manufacturing services during clinical development of tafoxiparin and the companies will jointly develop the commercial manufacturing of tafoxiparin. Opocrin is one of the most experienced European manufacturers of polysaccharides, such as low molecular weight heparins. Dilafor is a Karolinska Development portfolio company.

2014-10-08

CCS Healthcare and Lipidor cooperate on new skin care technology for use in new products

CCS Healthcare, one of the Nordic region’s largest manufacturers of skin care products, pharmaceuticals and hygiene products, licenses the new AKVANO® technology, developed by Lipidor AB.

2014-09-15

Recipharm and Pharmanest form collaboration for commercial manufacture and supply of SHACT

July 3rd 2014. Recipharm Karlskoga AB, specialized in the manufacture of semi-solid products, and Pharmanest AB, a Stockholm-based pharmaceutical company specializing in developing products for local pain relief in obstetrics and gynecology, are pleased to announce the formation of a new pharmaceutical manufacturing contract for SHACT.

2014-07-03

Aprea presents preclinical data at AACR – APR-246 re-sensitizes ovarian cancer cells to platinum compounds and doxorubicin

STOCKHOLM – April 7, 2014. Aprea AB today presented preclinical data at the American Association for Cancer Research (AACR) meeting in San Diego, USA. The data reveals that Aprea’s candidate drug APR-246, a compound that reactivates mutant p53, is able to resensitize ovarian cancer cells to platinum compounds and doxorubicin. A Phase Ib/II study with APR-246 in relapsed platinum sensitive ovarian cancer is currently open for recruitment. Aprea is part of the Karolinska Development portfolio.

2014-04-07

NephroGenex Prices Initial Public Offering of Common Stock

STOCKHOLM – February 11, 2014. NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the pricing of its initial public offering. The news will not have any material impact on Karolinska Development’s results and financial position.

2014-02-11

Dilaforette AB announced today the appointment of Christina Herder as new CEO

STOCKHOLM, SWEDEN - January 22, 2014. Dilaforette AB, a company in Karolinska Development’s portfolio, announced today the appointment of Christina Herder as new CEO. Christina Herder, PhD, MBA, will bring over 20 years of experience in product development and business development from the pharmaceutical industry.

2014-01-22

Aprea strengthens its board

Stockholm, Sweden – January 20, 2014. Aprea AB, a Karolinska Development portfolio company, announces that Bernd R. Seizinger has been elected as a new member of the board. Bernd R. Seizinger, M.D., Ph.D., is Chairman of Opsona Therapeutics Ltd. and former Vice President, Oncology Drug Discovery at Bristol-Myers Squibb, Associate Professor of Neuroscience at Harvard Medical School and Associate Geneticist and Director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital in Boston, MA, USA.

2014-01-20

Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms

STOCKHOLM – December 16, 2013. Umecrine Mood AB announced today that patient recruitment for the ongoing phase I/II study with UC1010 for the treatment of severe premenstrual symptoms (PMDD) has been completed. Umecrine Mood is part of the Karolinska Development portfolio.

2013-12-16

Umecrine Cognition signs partnering agreement with CleveXel Pharma

STOCKHOLM – October 23, 2013. Umecrine Cognition AB, a Karolinska Development portfolio company, today announced that the company has entered into a partnering agreement with CleveXel Pharma regarding the development of its lead program in hepatic encephalopathy.

2013-10-23

Athera elects new Chairman of the Board and moves to new premises

STOCKHOLM, SWEDEN –Sept 19, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that Gunnar Olsson, former head of the global CV/GI team in AstraZeneca, has been elected new Chairman of the Board. Earlier this year, Tomas Odergren, VP Clinical Development at Karolinska Development AB, joined the Board of Directors.

2013-09-19

Inhalation Sciences receives US Patent Approval for PreciseInhale

STOCKHOLM – September 18, 2013. Inhalation Sciences Sweden AB, a portfolio company of Karolinska Development, announces today that the company has received US Patent Approval for its flagship technology the PreciseInhale™ System.

2013-09-18

Athera and Medirista sign agreement to transfer the Annexin A5 project

STOCKHOLM, SWEDEN – Aug 23, 2013. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB. Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård. The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.

2013-08-23

Aprea presents preclinical data at AACR - Strong synergistic effect with APR-246 and cisplatin

STOCKHOLM – April 9, 2013. Aprea AB today presented preclinical data at the American Association for Cancer Research (AACR) meeting in Washington, DC, USA. The results from these studies show that Aprea’s lead candidate APR-246, a compound that reactivates mutant p53, acts synergistically with platinum compounds. Aprea, which is part of the Karolinska Development portfolio, is now preparing a Phase II study with APR-246 in platinum resistant ovarian cancer.

2013-04-09

Aprea to present at the American Association for Cancer Research (AACR) annual meeting in Washington, DC, in April 2013

STOCKHOLM – April 3, 2013. Aprea AB today announces that a poster entitled “Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients” will be presented at the upcoming AACR meeting in Washington, DC, USA, in April 2013. Aprea is a Karolinska Development portfolio company.

2013-04-03

Alzheimer antibody enters into Phase IIb

BioArctic’s monoclonal antibody for Alzheimer’s disease, BAN2401, has entered the next clinical study after successfully passed phase IIa. Safety and tolerability data indicate that BAN2401 is safe and well tolerated agent. Sixty Alzheimer patients received BAN2401 and 20 got placebo.

2013-02-05

Investigator sponsored Phase I/II study of AXL1717 in patients with brain tumors started in the US

STOCKHOLM, January 21, 2013. Axelar AB, a Karolinska Development AB portfolio company, announced today that an investigator sponsored Phase I/II study with AXL1717 in patients with malignant astrocytomas, a type of brain tumor, has commenced in the United States.

2013-01-21

Dilaforette is granted SEK 2.85m for development of sevuparin for the treatment of severe malaria

STOCKHOLM – November 2, 2012. Dilaforette announces today that it has been granted SEK 2.85m from the Swedish Governmental Agency for Innovation Systems, Vinnova, for the development of sevuparin, a new potential treatment for severe malaria.

2012-11-02

Pharmanest appoints Alan Raffensperger as Chairman of the Board

Stockholm, November 1, 2012. Today Pharmanest AB, a Karolinska Development portfolio company, announced that Alan Raffensperger, Per Langö and Gunilla Ekström have been elected as new members of the Board. Alan Raffensperger was elected Chairman. The Board of Pharmanest has hereby gained comprehensive experience in the commercialization of new, innovative products and is well prepared to progress the candidate drug SHACT, for pain relief in gynecological procedures.

2012-11-01

Low levels of anti-PC predict vein graft failure

STOCKHOLM, SWEDEN – October 25, 2012. Athera Biotechnologies AB, a Karolinska Development AB portfolio company, today announced that results from a new study were presented at the Pacific Northwest Vascular Society Annual Meeting in Vancouver, Canada. The data shows that low levels of plasma anti-PC, measured with Athera’s CVDefine® kit, are associated with a high risk for vein graft failure after bypass surgery.

2012-10-25

Biosergen AS appoints Gunilla Ekström as CEO

TRONDHEIM October 11, 2012. Biosergen AS, a Karolinska Development portfolio company, announced today the appointment of Gunilla Ekström as new CEO.

2012-10-11

XSpray announces major advance in the formulation of challenging oral Protein Kinase Inhibitors (PKI)

Stockholm, Sweden – October 10, 2012. XSpray, a Karolinska Development portfolio company, announces positive data from dog studies with their novel formulation strategy for PKIs. Plasma levels of nilotinib in dogs increased over 700% with the XSpray formulation when compared with the commercially available product in dogs with neutralized stomachs. In addition, XSpray has demonstrated an improvement in solubility in-vitro with novel formulations of a range of different marketed PKI’s.

2012-10-10

Axelar AB appoints Carl Harald Janson as CEO

STOCKHOLM, October 1, 2012. Axelar AB, a Karolinska Development AB portfolio company, announced today the appointment of Carl Harald Janson as new CEO.

2012-10-01

XSpray and Cerbios-Pharma announce partnership on the use of XSpray’s RightSizeTM technology

Stockholm, Sweden – September 4, 2012. XSpray Microparticles AB today announced a partnership with Cerbios-Pharma SA of Lugano, Switzerland for the joint development of HPAI (High Potency Active Ingredients). HPAI development will be provided by XSpray in Stockholm, while the cGMP production for clinical and commercial use will be carried out at Cerbios in Lugano.

2012-09-04

Akinion Pharmaceuticals announces the publication of preclinical results of AKN-028

STOCKHOLM, SWEDEN - August 6, 2012. Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, today announced that the article ”The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia” by Eriksson A. et al., has been published online in Blood Cancer Journal at www.nature.com/bcj.

2012-08-06

Investigational Cis-urocanic acid eye drops for dry eye syndrome well tolerated, in Phase 1 clinical study

Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to investigate the tolerability and safety of the ophthalmic product as well as pharmacokinetics after single and repeated dosing. In total, 37 healthy adult volunteers were recruited in the study.

2012-06-28

Lipidor and Cerbios-Pharma have signed an agreement for the co-development of an innovative topical delivery system

Lipidor AB of Stockholm, Sweden, and Cerbios-Pharma SA of Lugano, Switzerland, have signed an agreement to jointly develop dermatological products built on Lipidor’s novel formulation technology - AKVANO(TM). The first application is an API used in the treatment of psoriasis, in order to demonstrate the advantages toward classical formulations like ointments or creams.

2012-06-13

Axelar AB has presented Phase I/II data of AXL1717 at the American Society of Clinical Oncology (ASCO) Annual Meeting

STOCKHOLM, June 2, 2012. Axelar AB, a Karolinska Development AB portfolio company, today announced the release of a poster at The American Society of Clinical Oncology (ASCO) Annual Meeting with data from the Phase I/II trial of AXL1717 that was completed in 2011.

2012-06-02

Axelar to present at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2012

STOCKHOLM, May 15, 2012. Axelar AB, a Karolinska Development portfolio company, today announces that a poster will be presented at the ASCO meeting in Chicago, Illinois, USA in June 2012, containing data from the clinical phase I/II trial in cancer patients that was completed in 2011.

2012-05-15

Approved US patent for nano coating for implants

The medical device company Promimic has obtained U.S. patent approval for its nano-thin implant coating HAnano Surface. In addition, the company has shown that the surface enables the implant material PEEK integrate with bone.

2012-05-03

NeoDynamics awarded SEK 4 million from Vinnova

STOCKHOLM, SWEDEN – APRIL 3, 2012. NeoDynamics AB, a Karolinska Development portfolio company, has been awarded 4 million from Vinnova for their program Forska&Väx. The program is aimed at small and medium size companies in all industries that independently, or in collaboration with partners, can demonstrate a strong growth potential by investing in research, development and innovation.

2012-04-03

Annexin A5 at low doses prevents atherosclerosis – Study published in Atherosclerosis

Solna, Sweden, March 2nd, 2012 –Treatment with low doses of recombinant Annexin A5 prevents vascular remodelling in a preclinical study. These results were recently published in an article in Atherosclerosis.

2012-03-02

Study linking outcome in acute coronary syndromes to anti-PC published in International Journal of Cardiology

Solna, Sweden, February 7th, 2012 – Scientists conclude that measuring antibodies to phosporylcholine (anti-PC), using a simple blood-test, may provide important and independent information on the prognosis of heart attack patients, in a study just published on-line in International Journal of Cardiology. The testing was performed using Athera Biotechnologies CVDefine® kit

2012-02-07

Magnus Doverskog appointed as new CEO for Umecrine Cognition

Solna, February 1, 2012. Magnus Doverskog has been appointed as new CEO for Umecrine Cognition AB, one of Karolinska Development AB’s portfolio companies. His most recent position was as CEO for the Biotechnology Company IMED AB in Stockholm.

2012-02-01

Akinion Pharmaceuticals appoints Carl Harald Janson as CEO

STOCKHOLM, SWEDEN - January 9, 2012. Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, announced today the appointment of Carl Harald Janson as new CEO. Carl Harald Janson, MD, PhD and CEFA, has over 25 years of experience in medicine, pharmaceutical development and asset management.

2012-01-09

Aprea strengthens its board

Stockholm, Sweden – December 22, 2011. Aprea AB announces that Peter Buhl Jensen has been elected as a new member of the board. Peter Buhl Jensen is Professor in Clinical Oncology at Copenhagen University, MD, DMSc and former Chief Oncologist at the Department of Oncology, Ålborg Hospital.

2011-12-22

Athera Forms New Scientific Advisory Board – Professors Libby, Simoons, Wallentin and de Faire join

Solna, Sweden, November 11th, 2011 – Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the new Scientific Advisory Board is formed, including professors Peter Libby, Maarten Simoons, Lars Wallentin, and Ulf de Faire.

2011-11-11

Oncopeptides AB appoints Jakob Lindberg as CEO

STOCKHOLM, SWEDEN - October 21, 2011. Oncopeptides AB, a Karolinska Development AB portfolio company, today announced the appointment of Jakob Lindberg as new CEO. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB. For the last six years, Jakob has been Vice President and Venture Partner at Investor Growth Capital in Stockholm.

2011-10-21

NeoDynamics innovative cancer treatment featured on US news channel

STOCKHOLM - October 6, 2011. The US news channel ABC 7 recently featured NeoDynamics’ innovative and cost-effective treatment of breast cancer. The concept has been proved simple and reliable and a first clinical study with excellent results has been conducted at Capio St. Görans and Danderyds Hospital in Stockholm where 58 patients have been treated. NeoDynamics is partly owned by Karolinska Development.

2011-10-06

Aprea secures funding for further development of the anticancer compound APR-246

Stockholm, Sweden – September 9, 2011. Aprea AB today announced that it has secured SEK 20.4m (EUR 2.1m) which will allow the company to complete its planned continuation of its clinical study with APR-246 in patients with hematologic malignancies. The company also announced that Torbjörn Bjerke has been elected as a new member of the board.

2011-09-09

Athera receives allowance of key patent for CVD antibody therapy

Solna, Sweden, August 23th, 2011 – Athera Biotechnologies, part of the Karolinska Development portfolio, announced today that the US Patent Office intends to grant a key patent related to the Company's intellectual property covering its therapeutic antibody candidate PC-mAb. Following subsequent grant, the patent will provide strong protection for pharmaceutical uses of PC-mAb for the treatment of atherosclerosis and prevention of ischemic cardiovascular diseases. The corresponding European and Australian patents have already been granted and further applications are pending worldwide.

2011-08-23

Torbjörn Bjerke appointed Chairman of Pergamum AB

Torbjörn Bjerke, Chief Executive Officer, Karolinska Development AB (publ), was appointed Chairman of the Board of Directors following the Annual Shareholders’ Meeting in Pergamum AB on June 22, 2011.

2011-07-06

Karolinska Development portfolio overview 2011

STOCKHOLM - July 1, 2011. Today, Karolinska Development has published the 2011 portfolio overview. The document can be downloaded from www.karolinskadevelopment.com.

2011-07-01

ProNoxis AB raises SEK 4 million in directed new share issue

June 17, 2011 with operations proceeding as planned, ProNoxis AB has secured SEK 4 million in a new round of financing. Signalling confidence in ProNoxis development to date, lead investor LU Bioscience invested SEK 2.5 million and Karolinska Development SEK 1.5 million. They now hold 29.7 and 17.6 percent of ProNoxis, respectively. Redoxis AB holds the remaining 52.7 percent. At the end of last year, ProNoxis strengthened the board of directors with the appointments of Tomas Leanderson and Ulf Björkman, who both have extensive industry experience.

2011-06-17

Study mapping genetic and environmental links of anti-PC published in Atherosclerosis

Solna, Sweden, 30 May 2011 – Scientists suggest an independent role of anti-PC as a biomarker in cardiovascular disease in a study just published on-line in Atherosclerosis. The testing was performed using Athera Biotechnologies CVDefine® kit.

2011-05-30

Corrado Sablone joins Pergamum AB as Chief Financial Officer

Stockholm, May 30, 2011. Pergamum, a Swedish biotechnology company with focus on the development of new treatments for wounds and skin infections, today announced the hire of Corrado Sablone as Chief Financial Officer. Mr Sablone joins Pergamum from Coca Cola Enterprises Sverige AB, where he has been the Commercial Controlling Manager since 2006. Prior to Coca Cola, Corrado Sablone has served as business controller in several companies, including public international corporations such as Tetra Pak and Tradimus.

2011-05-30

Dilafor transfers the rights for sevuparin to Dilaforette

STOCKHOLM - May 17, 2011. Dilafor AB announces transfer of the rights for sevuparin, to Dilaforette AB. Sevuparin is being developed for the treatment of severe malaria and has successfully completed a clinical Phase I study. Karolinska Development is the majority owner of Dilafor with 54 percent of the company. Dilaforette is fully owned by Dilafor.

2011-05-17

Lena Wikingsson new CEO of Dilafor

STOCKHOLM, May 16, 2011. Lena Wikingsson has been appointed CEO of Dilafor AB. She has several years of experience from pharmaceutical development in leading positions within the pharmaceutical industry. She has, among others, been assessor of biotechnology products at the Swedish Medical Products Agency and CEO of Independent Pharmaceutica.

2011-05-16

Pergamum appoints Jan Nilsson as Chief Marketing Officer

Stockholm, May 13, 2011. Pergamum has appointed Jan Nilsson as Chief Marketing Officer and as Managing Director of the LL-37 program – Pergamum’s program for wound healing in chronic leg ulcers. Jan Nilsson has previously held a number of executive leadership positions within international life science companies. Also, he has worked as an executive consultant and advisor for a number of smaller biotechs.

2011-05-13

NeoDynamics’ innovative cancer treatment featured in Swedish science television program ”Vetenskapens Värld”

In ”Vetenskapens Värld” April 4, 2011, there was a NeoDynamics feature showing its innovative and cost-effective treatment of breast cancer. The concept has been proven simple and reliable in in-vitro tests, and a first clinical study with excellent results has been conducted at Capio St. Görans and Danderyds Hospital in Stockholm. As of today, around 50 patients have been treated.

2011-04-06

Promimic named as one of Sweden's hottest technology companies

Stockholm - Sweden – March 31, 2011, Promimic, 25 percent owned by Karolinska Development, has been chosen by the papers Affärsvärlden och Ny Teknik as one of Sweden's 33 Hottest Young technology companies for 2011. Promimic has been chosen for the company's nano-thin synthetic bone surface, which is considered to be unique and to have a large international market potential.

2011-03-31

Axelar’s AXL1717 to be presented at the American Association of Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida

Stockholm - Sweden – March 29, 2011. Axelar AB today announced that study results from the Phase I study evaluating AXL1717 for the treatment of squamous cell lung carcinoma will be presented at the American Association of Cancer Research annual meeting being held in Orlando, Florida. Axelar is part of the Karolinska Development portfolio of companies.

2011-03-29

FDA approval for surface based on synthetic bone

Gothenburg 10th February 2011 The biomaterial company Promimic has received 510(k) clearance for the implant surface HANANO™ Surface. The approval allows the company to market and sell the surface in the United States within the field of dental implants.

2011-02-10

XSpray receives innovation grant for nanoparticle technology

Stockholm - Sweden – December 06, 2010. XSpray Microparticles announced today that it has received a grant of SEK 2.3 million from Vinnova, the Swedish Agency for Innovation Systems. The grant will be used to expand the company’s RightSize™ nanoparticle technology for the development of innovative pharmaceutical formulations.

2010-12-06

Aprea to Present Preclinical Data about APR-246 at the American Society of Hematology Annual Meeting, in Orlando, USA

Stockholm - Sweden – November 8, 2010. Aprea AB today announced that encouraging data from its preclinical studies with APR-246 will be presented in a poster session at the upcoming 52nd ASH (American Society of Hematology) Annual Meeting and Exposition in Orlando, FL, USA, December 4-7, 2010.

2010-11-08

XSpray strengthens patent portfolio for breakthrough particle production technology

Stockholm, Sweden – November 04, 2010. XSpray Microparticles today announced that the US Patent and Trademark Office has granted a patent relating to the company’s particle production technology. XSpray’s RightSize™ Particle technology provides complete control over particle production, enhancing drug formulation options and optimizing the performance of challenging drug substances, such as poorly soluble compounds, inhaled compounds, and biomolecules.

2010-11-04

Bengt Å Johansson takes role as acting CEO of Dilafor. Anders Åsell is elected board member of Dilafor.

STOCKHOLM, October 25, 2010. Dilafor CEO Anders Åsell has decided to leave the company to assume the role as General Manager for Grifols in the Nordic countries. Bengt Å Johansson, chairman of Dilafor, takes on the role as acting CEO of Dilafor during the search for a replacement. Anders Åsell has been elected as new Dilafor board member.

2010-10-25

Gunilla Lundmark appointed as new CEO for Dilanest

STOCKHOLM, October 25 2010. Gunilla Lundmark has been appointed new CEO for Dilanest AB, a Karolinska Development portfolio company. She is currently Vice President at Q-Med, and will assume the position in January, 2011. Gunilla succeeds Anders Åsell who has decided to leave the company to assume the role as General Manager for Grifols in the Nordic countries.

2010-10-25

Ulf Björklund new CEO at Aprea

STOCKHOLM - Sweden – September 30, 2010. Ulf Björklund has been appointed new Chief Executive Officer (CEO) of Aprea. Ulf Björklund is today the CEO of OxyPharma. He will take up the position in October; the previous CEO Thomas Uhlin has in September left Aprea to join the Swedish Medical Products Agency. Ulf Björklund has a long extensive experience from the pharmaceutical industry, including small start up companies and big pharma. Prior to joining OxyPharma 2002 Ulf spent more then 15 years with Pharmacia. Aprea is now in the end of a Phase I study with their candidate drug APR-246 and is planning to start a Phase II study during the fall 2011.

2010-09-30

First clinical study started with BAN2401, a novel antibody targeting the neurotoxin believed to cause Alzheimer’s disease

STOCKHOLM - Sweden and Tokyo, Japan, September 2nd, 2010. Swedish biopharmaceutical company BioArctic Neuroscience AB (Headquarters: Stockholm, CEO: Dr. Pär Gellerfors) and Japanese pharmaceutical company Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Hauro Naito), announce today the start of the first clinical study with BAN2401 in patients with Alzheimer’s disease. BAN2401 is an antibody that targets the toxic amyloid aggregates believed to cause degeneration of brain cells leading to Alzheimer’s disease. The new treatment approach is expected to halt progression of the disease

2010-09-02

Athera signs distribution agreement in Scandinavia

STOCKHOLM, Sweden – August 27, 2010. Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of ”CVDefine” kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio

2010-08-27